Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma

Autor: Gennaro Ciliberto, Eliana Greissworth, Anna Crispo, Maurizio Montella, Alessandra Gavazza, George Lubas, Luigi Aurisicchio, Joseph A. Impellizeri
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Male
Electrochemotherapy
Cancer vaccine
Canine lymphoma
Genetic vaccine
TERT
040301 veterinary sciences
TERT
lcsh:Medicine
Kaplan-Meier Estimate
CHOP
Cancer Vaccines
General Biochemistry
Genetics and Molecular Biology
0403 veterinary science
03 medical and health sciences
Dogs
0302 clinical medicine
Antigen
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Cancer vaccine
Animals
Medicine
Canine lymphoma
Cyclophosphamide
Telomerase
Canine Lymphoma
business.industry
Research
Vaccination
lcsh:R
Cancer
04 agricultural and veterinary sciences
General Medicine
medicine.disease
Survival Analysis
Lymphoma
Kinetics
Doxorubicin
Vincristine
030220 oncology & carcinogenesis
Antibody Formation
Cancer research
Genetic vaccine
Prednisone
Female
Lymphoma
Large B-Cell
Diffuse
business
Diffuse large B-cell lymphoma
Zdroj: Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Journal of Translational Medicine
ISSN: 1479-5876
DOI: 10.1186/s12967-018-1738-6
Popis: Background we have recently shown that Tel-eVax, a genetic vaccine targeting dog telomerase (dTERT) and based on Adenovirus (Ad)/DNA Electro-Gene-Transfer (DNA–EGT) technology can induce strong immune response and increase overall survival (OS) of dogs affected by multicentric Diffuse Large B cell Lymphoma (DLBCL) when combined to COP therapy in a double-arm study. Here, we have utilized a clinically validated device for veterinary electroporation called Vet-ePorator™, based on Cliniporator™ technology currently utilized and approved in Europe for electrochemotherapy applications and adapted to electrogenetransfer (EGT). Methods 17 dogs affected by DLBCL were vaccinated using two Ad vector injections (Prime phase) followed by DNA–EGT (Boost phase) by means of a Vet-ePorator™ device and treated in the same time with a 27-week Madison Wisconsin CHOP protocol. The immune response was measured by ELISA assays using pool of peptides. Results No significant adverse effects were observed. The OS of vaccine/CHOP animals was 64.5 weeks, in line with the previous study. Dogs developed antibodies against the immunizing antigen. Conclusions Tel-eVax in combination with CHOP is safe and immunogenic in lymphoma canine patients. These data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other cancer types. More importantly, our findings may translate to human clinical trials and represent new strategies for cancer treatment.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje